Current perspectives on tocilizumab for the treatment of rheumatoid arthritis: a review

References

• MajithiaVGeraciSARheumatoid arthritis: diagnosis and managementAm J Med20071201193693917976416
   PubMed Web of Science ®Google Scholar
• Al-ShakarchiIFragility Fractures in Rheumatoid Arthritis – A systematic review of the literatureProceedings of the British Society of Rheumatology ConferenceApril 21–23, 2010Birmingham, UK
   Google Scholar
• SmolenJSAletahaDKoellerMWeismanMHEmeryPNew therapies of rheumatoid arthritisLancet200737096021861187417570481
   PubMed Web of Science ®Google Scholar
• NishimotoNYoshiazakiKMaedaKToxicity, pharmacokinetics, and dose-finding study of repetitive treatment with the humanized anti-interleukin 6 receptor antibody MRA in rheumatoid arthritis. Phase I/II clinical studyJ Rheumatol20033071426143512858437
   PubMed Web of Science ®Google Scholar
• Navarro-MillánISinghJCurtisJRSystematic review of Tocilizumab for rheumatoid arthritis: A new biologic agent targeting the Interleukin-6 receptorClin Ther2012344788802 e322444783
   PubMed Web of Science ®Google Scholar
• HashizumeMMiharaMThe roles of Interleukin-6 in the Pathogenesis of Rheumatoid ArthritisArthritis20112011
   Google Scholar
• OldfieldVDhillonSPloskerGLTocilizumab: a review of its use in the management of rheumatoid arthritisDrugs200969560963219368420
   PubMed Web of Science ®Google Scholar
• FiresteinGSEvolving concepts of rheumatoid arthritisNature2003423693735636112748655
   PubMed Web of Science ®Google Scholar
• GaffoASaagKGCurtisJRTreatment of rheumatoid arthritisAm J Health Syst Pharm200663242451246517158693
   PubMed Web of Science ®Google Scholar
• GenoveseMCMcKayJDNasonovELInterleukin-6 receptor inhibition with tocilizumab reduces disease activity in rheumatoid arthritis with inadequate response to disease-modifying antirheumatic drugs. The Tocilizumab in combination with traditional disease modifying anti-rheumatic drug therapy studyArthritis Rheum200858102968298018821691
   PubMed Web of Science ®Google Scholar
• OlsenNJSteinCMNew drugs for rheumatoid arthritisN Engl J Med2004350212167217915152062
   PubMed Web of Science ®Google Scholar
• HushawLLSawaquedRSweisGCritical appraisal of tocilizumab in the treatment of moderate to severe rheumatoid arthritisTher Clin Risk Manag2010614315220421913
   PubMed Web of Science ®Google Scholar
• FeldmannMMainiRNAnti-TNF α therapy of rheumatoid arthritis; what have we learnt?Ann Rev Immunol20011916319611244034
   PubMed Web of Science ®Google Scholar
• MainiRNTaylorPCSzechinsjiJCHARISMA Study GroupDouble-blind randomized Controlled clinical trial of the interleukin-6 receptor antagonist, Tocilizumab, in European patients with rheumatoid arthritis who had an incomplete response to methotrexateArthritis Rheum20065492817282916947782
   PubMed Web of Science ®Google Scholar
• HetlandMLChristensenIJTarpUAll Departments of Rheumatology in DenmarkDirect comparison of treatment responses, remission rates, and drug adherence in patients with rheumatoid arthritis treated with adalimumab, etanercept, or infliximab: results from eight years of surveillance of clinical practice in the nationwide DANIBO registryArthritis Rheum2010621223220039405
   PubMed Web of Science ®Google Scholar
• NishimotoNKishimotoTHumanized antihuman IL-6 receptor antibody, tocilizumabHandb Exp Pharmacol200818115116018071945
   PubMedGoogle Scholar
• SinghJABegSLopez-OlivoMAtocilizumab for rheumatoid arthritis: a cochrane systematic reviewJ Rheumatol2011381102020952462
   PubMed Web of Science ®Google Scholar
• DayerJChoyETherapeutic targets in rheumatoid arthritis: the interleukin-6 receptorRheumatology2010491152419854855
   PubMed Web of Science ®Google Scholar
• HiranoTYasukawaKHaradaHComplementary DNA for a novel human interleukin (BSF-2) that induces B lymphocytes to produce immunoglobulinNature1986324609273763491322
   PubMed Web of Science ®Google Scholar
• KishimotoTInterleukin-6: from basic science to medicine-40 years in immunologyAnn Rev Immunol20052312115771564
   PubMed Web of Science ®Google Scholar
• MimaTNishimotoNClinical value of blocking Il-6 receptorCurr Opin Rheumatol200921322423019365268
   PubMed Web of Science ®Google Scholar
• KishimotoTInterleukin-6 and its receptor in autoimmunityJ Autoimmun19925Suppl A1231321380241
   PubMed Web of Science ®Google Scholar
• ChoyEHIsenbergDAGarrodTTherapeutic benefit of blocking Interleukin-6 activity with an anti-interleukin-6 receptor monoclonal antibody in rheumatoid arthritis. A randomized, double-blind, placebo-controlled, dose-escalation trialArthritis Rheum200246123143315012483717
   PubMed Web of Science ®Google Scholar
• FonsecaJESantosMJCanhãoHChoyEInterleukin-6 as a key player in systemic inflammation and joint destructionAutoimmun Rev20098753854219189867
   PubMed Web of Science ®Google Scholar
• HiranoTMatsudaTTurnerMExcessive production of interleukin 6/B cell stimulatory factor-2 in rheumatoid arthritisEur J Immunol19881811179718012462501
   PubMed Web of Science ®Google Scholar
• OkudaYReview of tocilizumab in the treatment of rheumatoid arthritisBiologics200821758219707430
   PubMedGoogle Scholar
• Rose-JohnSSchellerJElsonGJonesSAInterleukin-6 biology is coordinated by membrane-bound and soluble receptors: role in inflammation and cancerJ Leukoc Biol200680222723616707558
   PubMed Web of Science ®Google Scholar
• HiranoTInterleukin 6 and its receptor: ten years laterInt Rev Immunol1998163–42492849505191
   PubMedGoogle Scholar
• WardLDHowlettGJDiscoloGHigh affinity interleukin-6 receptor is a hexameric complex consisting of two molecules each of interleukin-6 receptor and gp-130J Biol Chem19942693723286232898083235
   PubMed Web of Science ®Google Scholar
• LallyFSmithEFilerAA novel mechanism of neutrophil recruitment in a coculture model of the rheumatoid synoviumArthritis Rheum200552113460340916255036
   PubMed Web of Science ®Google Scholar
• DasguptaBCorkillMKirkhamBGibsonTPanayiGSerial estimation of interleukin-6 as a measure of systemic disease in rheumatoid arthritisJ Rheumatol199219122251556695
   PubMed Web of Science ®Google Scholar
• KotakeSSatoKKimKJInterleukin-6 and soluble interleukin-6 receptors in the synovial fluid from rheumatoid arthritis patients are responsible for osteoclast-like cell formationJ Bone Miner Res199611188958770701
   PubMed Web of Science ®Google Scholar
• NakaharaHSongJSugimotoMAnti-interleukin-6 receptor antibody therapy reduces vascular endothelial growth factor (VEGF) production in rheumatoid arthritisArthritis Rheum20034861521152912794819
   PubMed Web of Science ®Google Scholar
• NishimotoNInterleukin-6 as a therapeutic target in candidate inflammatory diseasesClin Pharmacol Ther201087448348720182422
   PubMed Web of Science ®Google Scholar
• Tocilizumab for the treatment of rheumatoid arthritis (rapid review of technology appraisal guidance 198)NICE technology appraisal guidance 247 [webpage on the Internet]LondonNational Institute for Health and Clinical Excellence2012 Available from: http://guidance.nice.org.uk/TA198Accessed Sep 12, 2012
   Google Scholar
• FelsonDTAndersonJJBoersMAmerican College of Rheumatology. Preliminary definition of improvement in rheumatoid arthritisArthritis Rheum19953867277357779114
   PubMed Web of Science ®Google Scholar
• van GestelAMHaagsmaCJvan RielPLValidation of rheumatoid arthritis improvement criteria that include simplified joint countsArthritis Rheum19984110184518509778226
   PubMed Web of Science ®Google Scholar
• van der HeijdeDMvan’t HofMAvan RielPLJudging disease activity in clinical practice in rheumatoid arthritis: first step in the development of a disease activity scoreAnn Rheum Dis199049119169202256738
   PubMed Web of Science ®Google Scholar
• NishimotoNYoshizakiKMiyasakaNTreatment of rheumatoid arthritis with humanized anti–interleukin-6 receptor antibody – a multicenter, double-blind, placebo-controlled trialArthritis Rheum20045061761176915188351
   PubMed Web of Science ®Google Scholar
• NishimotoNMiyasakaNYamamotoKKawaiSTakeuchiTAzumaJLong-term safety and efficacy of tocilizumab, an anti-IL-6 receptor monoclonal antibody, in monotherapy, in patients with rheumatoid arthritis (the STREAM study): evidence of safety and efficacy in a 5-year extension studyAnn Rheum Dis200968101580158419019888
   PubMed Web of Science ®Google Scholar
• JonesGSebbaAGuJComparison of tocilizumab monotherapy versus monotherapy in patients with moderate to severe rheumatoid arthritis: the AMBITION studyAnn Rheum Dis2010691889619297346
   PubMed Web of Science ®Google Scholar
• NishimotoNMiyasakaNYamamotoKStudy of active controlled tocilizumab monotherapy for rheumatoid arthritis patients with an inadequate response to methotrexate (SATORI): significant reduction in disease activity and serum vascular endothelial growth factor by IL-6 receptor inhibition therapyMod Rheumatol2009191121918979150
   PubMed Web of Science ®Google Scholar
• SmolenJSBeaulieuARubbert-RothAOPTION InvestigatorsEffect of interleukin-6 receptor inhibition with tocilizumab in patients with rheumatoid arthritis (OPTION study): a double-blind, placebo-controlled, randomized trialLancet2008371961798799718358926
   PubMed Web of Science ®Google Scholar
• EmeryPKeystoneETonyHPIL-6 receptor inhibition with tocilizumab improves treatment outcomes in patients with rheumatoid arthritis refractory to anti-tumor necrosis factor biological: results from a 24-week multicenter randomized placebo-controlled trialAnn Rheum Dis200867111516152318625622
   PubMed Web of Science ®Google Scholar
• NishimotoNHashimotoJMiyasakaNStudy of active controlled monotherapy used for rheumatoid arthritis, an IL-6 inhibitor (SAMURAI): evidence of clinical and radiographic benefit from an x-ray reader-blinded randomized controlled trial of tocilizumabAnn Rheum Dis20076691162116717485422
   PubMed Web of Science ®Google Scholar
• KremerJMBlancoRBrzoskoMTocilizumab inhibits structural joint damage in rheumatoid arthritis patients with inadequate responses to Methotrexate – results from the double-blind treatment phase of a randomized placebo-controlled trial of tocilizumab safety and prevention of structural joint damage at one yearArthritis Rheum201163360962121360490
   PubMed Web of Science ®Google Scholar
• CampbellLChenCBhagatSSParkerRAÖstörAJRisk of adverse events including serious infections in rheumatoid arthritis patients treated with tocilizumab: a systematic literature review and meta-analysis of randomized controlled trialsRheumatology (Oxford)201150355256221078627
   PubMed Web of Science ®Google Scholar
• PuolakkaKBlåfieldHKauppiMCost-effectiveness modeling of sequential biologic strategies for the treatment of moderate to severe rheumatoid arthritis in FinlandOpen Rheumatol J20126384322582103
   PubMedGoogle Scholar
• SchoelsMWongJScottDLEconomic aspects of treatment options in rheumatoid arthritis: a systematic literature review informing the EULAR recommendations for the management of rheumatoid arthritisAnn Rheum Dis2010696995100320447950
   PubMed Web of Science ®Google Scholar
• DiamantopoulosABenucciMCapriSEconomic evaluation of tocilizumab combination in the treatment of moderate-to-severe rheumatoid arthritis in ItalyJ Med Econ201215357658522313326
   PubMedGoogle Scholar
• DougadosMKisselKSheeranTAdding tocilizumab or switching to tocilizumab monotherapy in methotrexate inadequate responders: 24-week symptomatic and structural results of a 2-year randomized controlled strategy trial in rheumatoid arthritis (ACT-RAY)Ann Rheum Dis2013721435022562983
   PubMed Web of Science ®Google Scholar